May 19, 2021 -- Medicago and GlaxoSmithKline (GSK) announced positive interim phase II results for their adjuvanted COVID-19 vaccine candidate.
Medicago's plant-based vaccine, coronavirus viruslike particle (CoVLP), which has been tested with GSK's adjuvant, showed a similar antibody response in adults and elderly individuals after they received two doses. Those vaccinated experienced neutralizing antibody responses that were 10 times higher than those who were recovering from the novel coronavirus.
No severe adverse events were reported, according to the companies.
The companies launched the phase III trial of the vaccine candidate in March 2021 and will enroll up to 30,000 individuals worldwide.